After BridgeBio (BBIO) announced positive data from cohort 5 of its PROPEL2 study evaluating infigratinib in children with achondroplasia, BofA said the firm thinks Bridgebio’s data have a positive read-through to Tyra Biosciences’ (TYRA) lead asset TYRA-300. In preclinical studies, TYRA-300 delivered better bone growth in murine models compared to infigratinib, noted the firm, which has a Buy rating and $23 price target on Tyra shares.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TYRA:
- Tyra Biosciences price target raised to $17 from $15 at H.C. Wainwright
- Opco views BridgeBio data as good news for Tyra Biosciences
- Tyra Biosciences price target raised to $15 from $12 at H.C. Wainwright
- Tyra Biosciences price target raised to $25 from $17 at Oppenheimer
- Tyra Biosciences expands development of TYRA-300 into achondroplasia
